End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
781,000 KRW | 0.00% | -1.26% | +2.76% |
May. 06 | Samsung Group Firms Set to Invest in US-based Latus Bio | MT |
Apr. 25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 52% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.76% | 41.08B | A- | ||
-0.07% | 91.42B | A- | ||
-9.06% | 34.26B | B- | ||
+55.32% | 25.27B | A | ||
-16.61% | 15.27B | C | ||
-9.14% | 12.81B | B- | ||
-12.11% | 11.6B | D+ | ||
-43.61% | 11.42B | B | ||
+7.79% | 9.16B | B+ | ||
-7.49% | 8.22B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A207940 Stock
- Ratings Samsung Biologics Co.,Ltd.